Retrospective-prospective Study to Evaluate Treatment Management and Outcomes of Patients With Waldenström's Macroglobulinemia (WM) Treated in Italy According to the Zanubrutinib (Brukinsa®) Compassionate Use Program (CUP) and in Common Practice Following Commercial Approval.
Clinical trial NCT06441214 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT06441214
- Sponsor
- Fondazione Italiana Linfomi - ETS
- Status
- ACTIVE_NOT_RECRUITING
- Study type
- OBSERVATIONAL
- Start date
- 2024-12-13
- Primary completion
- 2026-12-01
- Enrollment
- 212
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.